GKWIM
EW icon

Gerber Kawasaki Wealth & Investment Management’s Edwards Lifesciences EW Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-483
Closed -$54K – 536
2021
Q3 		$54K Buy
+483
New +$55.1K 0.01% 313

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's EW Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of Edwards Lifesciences (EW) in Q4 2021, closing a stake of 483 shares — an estimated $54K sold.

Gerber Kawasaki Wealth & Investment Management first reported a position in EW in Q3 2021 and held it in 1 quarter. The position peaked at $54K in Q3 2021. 1,321 funds tracked by Wall St. Rank hold EW as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining Edwards Lifesciences position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 483 Edwards Lifesciences shares in Q4 2021, an estimated $54K.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in Edwards Lifesciences in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's Edwards Lifesciences position peaked at $54K in Q3 2021.
  • 1,321 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.